See more : Pacific Assets Trust plc (PAC.L) Income Statement Analysis – Financial Results
Complete financial analysis of Core One Labs Inc. (CLABF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Core One Labs Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Qi An Xin Technology Group Inc. (688561.SS) Income Statement Analysis – Financial Results
- IonQ, Inc. WT (IONQ-WT) Income Statement Analysis – Financial Results
- National Westminster Bank Plc 9% SER’A’NON-CUM PRF GBP1 (NWEAF) Income Statement Analysis – Financial Results
- Weconnect Tech International, Inc. (WECT) Income Statement Analysis – Financial Results
- ADvTECH Limited (ADH.JO) Income Statement Analysis – Financial Results
Core One Labs Inc. (CLABF)
About Core One Labs Inc.
Core One Labs Inc. operates as a biotechnology research and technology life sciences company. The company focuses on bringing psychedelic medicines to market through novel delivery systems, psychedelic assisted psychotherapy, and API grade psilocybin manufacturing. Its CannaStrips technology produces infused strips that allow for bioavailability of cannabis constituents. The company also offers consulting, financing, and micro cultivation services, as well as operates medical and wellness clinics. In addition, it provides natural health products; and news dissemination services. The company was formerly known as Lifestyle Delivery Systems Inc. and changed its name to Core One Labs Inc. in September 2019. Core One Labs Inc. was incorporated in 2010 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 458.54K | 431.62K | 0.00 | 5.04M | 4.08M | 191.13K | 56.09K | 58.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 42.20K | 38.77K | 0.00 | 5.71M | 5.77M | 0.00 | 0.00 | 1.60K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 416.34K | 392.85K | 0.00 | -669.57K | -1.69M | 191.13K | 56.09K | 56.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 90.80% | 91.02% | 0.00% | -13.28% | -41.40% | 100.00% | 100.00% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 80.34K | 627.29K | 97.91K | 1.12M | 1.12M | 2.71M | 65.08K | 59.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 8.36M | 5.47M | 8.13M | 7.77M | 8.67M | 1.63M | 920.79K | 304.70K | 328.25K | 459.34K | 260.27K |
| Selling & Marketing | 0.00 | 3.71M | 1.03M | 1.42M | 1.29M | 1.78M | 112.87K | 8.77K | 15.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 8.17M | 12.07M | 6.50M | 9.56M | 9.06M | 10.44M | 1.74M | 929.56K | 319.70K | 328.25K | 459.34K | 260.27K |
| Other Expenses | 0.00 | 37.30K | 614.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.25M | 12.64M | 7.14M | 14.67M | 10.24M | 13.16M | 2.00M | 1.11M | 430.17K | 328.25K | 459.34K | 260.27K |
| Cost & Expenses | 8.30M | 12.64M | 7.14M | 20.38M | 16.01M | 13.16M | 2.00M | 1.11M | 430.17K | 328.25K | 459.34K | 260.27K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 4.34K | 12.65K | 0.00 | 752.00 | 2.07K | 2.57K | 109.00 | 51.00 |
| Interest Expense | 1.37K | 22.25K | 16.47K | 575.41K | 130.29K | 32.65K | 0.00 | 20.01K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 42.20K | 38.77K | 206.30K | 6.09M | 54.74K | 6.92K | 187.56K | 121.51K | 110.47K | 279.94K | 0.00 | 0.00 |
| EBITDA | -7.80M | -12.13M | -6.52M | -9.25M | -11.87M | -12.97M | -1.75M | -931.17K | -319.70K | -212.13K | -459.34K | -260.27K |
| EBITDA Ratio | -1,699.99% | -2,811.50% | 0.00% | -183.52% | -290.79% | -6,786.39% | -3,125.56% | -1,597.26% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.84M | -12.17M | -6.52M | -15.34M | -11.92M | -12.98M | -1.94M | -1.07M | -430.17K | -492.07K | -459.34K | -260.27K |
| Operating Income Ratio | -1,709.20% | -2,820.48% | 0.00% | -304.24% | -292.13% | -6,790.01% | -3,459.98% | -1,841.30% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.14M | -24.82M | -39.75M | -5.74M | -1.10M | -154.02K | -925.78K | -133.99K | 2.07K | -116.12K | 109.00 | 0.00 |
| Income Before Tax | -15.98M | -37.05M | -46.90M | -21.65M | -13.15M | -13.16M | -2.87M | -1.21M | -428.10K | -441.80K | -459.23K | 0.00 |
| Income Before Tax Ratio | -3,485.36% | -8,585.16% | 0.00% | -429.47% | -322.33% | -6,887.69% | -5,110.62% | -2,069.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00 | 59.55K | 7.71M | 386.16K | -736.22K | -535.24K | 0.00 | 20.01K | 0.00 | -166.39K | 0.00 | 260.22K |
| Net Income | -15.98M | -37.05M | -54.62M | -21.46M | -12.29M | -12.60M | -2.87M | -1.21M | -428.10K | -441.80K | -459.23K | -260.22K |
| Net Income Ratio | -3,485.36% | -8,585.16% | 0.00% | -425.72% | -301.09% | -6,590.56% | -5,110.62% | -2,069.84% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.49 | -2.57 | -10.27 | -15.25 | -10.56 | -17.52 | -8.71 | -7.79 | -12.06 | -14.11 | -14.76 | -10.65 |
| EPS Diluted | -0.49 | -2.57 | -10.27 | -15.25 | -10.56 | -17.52 | -8.71 | -7.79 | -12.06 | -14.11 | -14.76 | -10.65 |
| Weighted Avg Shares Out | 32.71M | 14.42M | 5.32M | 1.41M | 1.16M | 718.83K | 328.95K | 154.82K | 35.50K | 31.32K | 31.11K | 24.42K |
| Weighted Avg Shares Out (Dil) | 32.71M | 14.42M | 5.32M | 1.41M | 1.16M | 718.83K | 328.95K | 154.82K | 35.50K | 31.32K | 31.11K | 24.42K |
Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC
VANCOUVER, British Columbia, April 24, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce its wholly owned subsidiary Vocan, has entered into a Collaborative Research Agreement with...
Core One Labs' Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research and technology company focused on bringing psychedelic medicines to market through...
Core One Labs Negotiates Milestone Acquisition With Akome Biotech Ltd.
VANCOUVER, BC / ACCESSWIRE / April 17, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company") a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce it has signed letter...
Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp.
VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company" or "Core One") announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth Opportunity Corporation) (PBIC) ("PBIC") to rescind...
Emerging Markets Report: A Moment for the Mushroom
Core One Labs Looking to Compete in Psylocibin with a Proprietary Offering at a Fraction of Current Market Cost Core One Labs Looking to Compete in Psylocibin with a Proprietary Offering at a Fraction of Current Market Cost
Core One Labs Completes Acquisition of Ketamine Infusions Centers of Texas Representing the Company's First Psychedelics Clinic in the U.S. and Announces Fast Entry Inclusion in the Horizons Psychedelic ETF
VANCOUVER, BC / ACCESSWIRE / March 31, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) WKN: A2P8K3) ("Core One" or the "Company"), a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel...
Core One Labs Appoints Dr. Stephen Peach as Head of Patient Research
VANCOUVER, BC / ACCESSWIRE / March 28, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the "Company") is pleased to announce that its wholly owned subsidiary Rejuva Mental Health Clinic (the "Clinic") has retained Dr. Stephen Peach as Lead Physician....
Core One Labs Files Application to List its Common Shares on NASDAQ
VANCOUVER, British Columbia, March 20, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (“Core One” or the “Company”) is pleased to announce that it has filed an application to list its common...
Core One Labs to Commence Trading in the US on OTC Pink Market
VANCOUVER, BC / ACCESSWIRE / March 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN: A2P8K3) (the "Company") a research and technology company focused on life sciences and bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy,...
Psychedelic Expert Core One Labs Reports Milestone Acquisition
The Developer of Psychedelic Treatments Enters the Telehealth Space with Access to Close to 80,000 Clinic Patients VANCOUVER, BC / ACCESSWIRE / March 12, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") announces...
Source: https://incomestatements.info
Category: Stock Reports